These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35069416)

  • 41. Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine.
    Youn MS; Kim N; Lee MJ; Kim M
    J Clin Neurol; 2024 May; 20(3):300-305. PubMed ID: 38713076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
    Raffaelli B; Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Reuter U
    J Headache Pain; 2022 Mar; 23(1):40. PubMed ID: 35350990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 45. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 46. Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines.
    Katsuki M; Kashiwagi K; Kawamura S; Koh A
    Cureus; 2023 Jan; 15(1):e33689. PubMed ID: 36788886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
    Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
    J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice.
    Cantarelli L; Pestana Grafiña D; Gonzalez Perez A; García Gil S; Gutiérrez Nicolás F; Ramos Santana E; Navarro Dávila MA; Otazo Pérez SM; Calzado Gómez G; Perez Reyes S; Nazco Casariego GJ
    Ann Pharmacother; 2023 Apr; 57(4):416-424. PubMed ID: 35979920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
    Sevivas H; Fresco P
    Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.
    Talbot J; Stuckey R; Wood N; Gordon A; Crossingham G; Weatherby S
    Eur J Hosp Pharm; 2024 Jan; ():. PubMed ID: 38182276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
    Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D
    J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
    Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
    J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Moskatel LS; Graber-Naidich A; He Z; Zhang N
    Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
    Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.
    Alsaadi T; Suliman R; Santos V; Al Qaisi I; Carmina P; Aldaher B; Haddad S; Bader Y
    Neurol Ther; 2024 Apr; 13(2):465-473. PubMed ID: 38361080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
    Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
    Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
    Andreou AP; Fuccaro M; Hill B; Murphy M; Caponnetto V; Kilner R; Lambru G
    J Headache Pain; 2022 Nov; 23(1):139. PubMed ID: 36333710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study.
    Jaimes A; Gómez A; Pajares O; Rodríguez-Vico J
    Pain Pract; 2023 Apr; 23(4):349-358. PubMed ID: 36507609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.